IL17A and psoriasis: A meta-estimate on the risk of respiratory tract infections (RTIs) and symptoms in patients with psoriasis treated with IL-17 inhibitor biologics found an increased risk of RTIs compared with placebo (odds ratio, 1.56; 95% CI:1.04–2.33) (42).